本文已被:浏览 525次 下载 1737次
Received:October 21, 2022 Published Online:June 20, 2023
Received:October 21, 2022 Published Online:June 20, 2023
中文摘要: 肺癌最常见的分型为非小细胞型肺癌(NSCLC),占肺癌的80%~85%,而且在发展过程中肿瘤极易转移至脑部,严重影响患者的治疗预后以及生存质量。目前,肺癌脑转移的主要治疗方案是手术、化疗、放疗、靶向治疗和免疫治疗。近年来,免疫检查点抑制剂的应用取得了突破,一些联合免疫疗法已经获得临床批准。根据《中国非小细胞肺癌免疫检查点抑制剂治疗专家共识》,已有一定的研究显示免疫治疗可应用于晚期NSCLC的治疗。免疫治疗犹如一把双刃剑,其实际临床意义仍需进一步探讨,本文回顾了非小细胞肺癌脑转移的免疫疗法的进展,探究肺癌脑转移患者更合理的临床治疗方案。
Abstract:The most common subtype of lung cancer is non-small cell lung cancer (NSCLC) , accounting for 80% to 85% of lung cancer. During the development process, the tumor is easily metastasized to the brain, seriously affecting the treatment prognosis and quality of life of patients. At present, the main treatment options for brain metastasis of lung cancer are surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. In recent years, breakthroughs have been made in the application of immune checkpoint inhibitors, and some combination immunotherapies have been clinically approved. According to the Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer, there have been certain studies showing that immunotherapy can be applied to the treatment of advanced NSCLC. Immunotherapy is like a double-edged sword, and its practical clinical significance still needs further exploration. This article reviews the progress of immunotherapy for brain metastasis of NSCLC and explores more reasonable clinical treatment plans for patients with brain metastasis of lung cancer.
keywords: Non-small cell lung cancer Brain metastasis Immunotherapy Immune checkpoint inhibitor Programmed cell death receptor Radiotherapy Chemotherapy Targeted therapy Anti angiogenic therapy
文章编号: 中图分类号:R734.2 文献标志码:A
基金项目:南充市 2020 年市校科技战略合作专项自由探索项目 (20SXQT0071
Author Name | Affiliation |
CHEN Xulan, LI Ningfu, XIAO Jianbo, YANG Mingjun, GUI Yan | Oncology Department, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China |
Author Name | Affiliation |
CHEN Xulan, LI Ningfu, XIAO Jianbo, YANG Mingjun, GUI Yan | Oncology Department, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China |
引用文本: